Obesity medicine that’s effective has been around for a very long time. Enter Semaglutide (sold as Ozempic and Wegovy), which helps people improve weight-related health, including Reducing risk Suffering a heart attack or stroke, while also silencing the “eating noise”.
As the demand for semaglutide increases, so does Claims That taking it’s “cheating” or “the easy way” to shed some pounds.
We don't tell individuals who need statin drugs to treat high cholesterol or drugs to regulate hypertension that they’re cheating or taking the simple way out.
Nor should we shame people taking semaglutide. It is a drug used to treat diabetes and obesity that requires long-term administration and comes with advantages in addition to risks and uncomfortable side effects. When prescribed for obesity, it’s given together with advice on food plan and exercise.
How it really works?
Semaglutide a Glucagon-like peptide-1 receptor agonist (GLP-1RA). This means it makes your body's own glucagon-like peptide-1 hormone, called GLP-1 For short, higher work.
GLP-1 is released by cells in your gut when this happens. Detects increased nutrient levels after eating. It stimulates the production of insulin, which lowers blood sugar.
GLP-1 also slows gastric emptying, which makes you are feeling fuller, and reduces hunger and feelings of reward after eating.
GLP-1 receptor agonist (GLP-1RA) drugs like Ozempic help the body's own GLP-1 work higher by mimicking and increasing its motion.
Some studies have shown that GLP-1 is released less after eating. Adults with obesity or type 2 diabetes in comparison with adults with normal glucose tolerance. So having less circulating GLP-1 in your blood means you don't feel full after eating and get hungry again before individuals who produce more.
GLP-1 has a really short half-life. Two minutes. Therefore, GLP-1RA drugs were designed to have an roughly long half-life. Seven days. That's why semaglutide is given as a weekly injection.
What can users expect? What does the research say?
A better dose of semaglutide is beneficial for the treatment of obesity than for the management of type 2 diabetes (2.4mg vs 2.0mg weekly).
A big group of Randomized controlled trialsCalled the STEP trials, all tested weekly 2.4mg semaglutide injections versus different interventions or placebo medication.
Trials lasting 1.3–2 years involved weekly injections of two.4 mg of semaglutide. 6-12% led to greater weight loss. Comparisons with placebo or alternative interventions. Average weight change relies on how long drug treatment lasts and the length of follow-up.
fcm82/shutterstock
Weight loss because of Semaglutide also a Decreased systolic and diastolic blood pressure A decrease of about 4.8 mmHg and a pair of.5 mmHg, respectively Triglyceride levels (a kind of blood fat) and Better physical function.
Another recent trial in adults with pre-existing heart disease and obesity, but without type 2 diabetes, found adults receiving 2.4mg semaglutide injections weekly. 20% less risk Specific cardiovascular events, including death from non-fatal heart attack, stroke or heart problems, after three years of follow-up.
Who is eligible for semaglutide?
Australia's regulator, the Therapeutic Goods Administration (TGA). Approved Semaglutide, for the treatment of type 2 diabetes, is sold as Ozempic.
However, because of the shortage, the TGA advised doctors not to start out recent Ozempic prescriptions for “off-label uses” corresponding to obesity treatment and the Pharmaceutical Benefits Scheme doesn’t currently subsidize off-label use.
The TGA has Vigovi is approved for the treatment of obesity. But it’s currently not available in Australia.
When it is accessible, doctors will have the option to prescribe. Semaglutide for the treatment of obesity In combination with lifestyle interventions (including food plan, physical activity and psychological support) in adults with obesity (BMI of 30 or above) or BMI of 27 or above who even have weight-related medical complications.
What else do it’s essential do during Ozempic treatment?
Checking the main points of Components of the STEP trial intervention, it is obvious that the participants have put in lots of effort and time. In addition to taking medication, people had temporary lifestyle counseling sessions with a dietitian or other health skilled at the very least every 4 weeks in most trials.
The support session was designed to assist people eat 2,000 kilojoules (500 calories) lower than their energy needs per day and perform 150 minutes of exercise. Moderate physical activitycorresponding to brisk walking, dancing and gardening every week.
The STEP trials differed in other components, with follow-up time periods various from 68 to 104 weeks. The aim of those trials was to point out the effect of adding medication on top of other lifestyle advice.
Elena Nechizhenova/Shutterstock
Oh A review of obesity drug trials People said they needed less. Cognitive Behavioral Training To help them survive with low energy intake. This is one aspect where drug treatment could make it a bit of easier. Lack of appetite and environmental food cues “switching off” may mean that less support is required for goal setting, self-monitoring of food intake, and avoidance of food triggers.
But what are the uncomfortable side effects?
Semaglutide Side Effects involved in Nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain.
In one study this led to Discontinuation of medication in 6% of individuals, but interestingly in 3% of individuals taking placebos.
More serious uncomfortable side effects include gallbladder disease, acute pancreatitis, hypoglycemia, acute kidney disease and injection site reactions.
To reduce the chance or severity of uncomfortable side effects, The dose of medicine is increased very slowly Once the total dose and response is achieved over months, research suggests it’s essential take it long-term.
Given this long-term commitment, and associated High out-of-pocket costs for medicationsin relation to taking semaglutide to treat obesity, it may well be considered “cheating”.